NASDAQ:QNCX Quince Therapeutics Q2 2026 Earnings Results & Report $31.73 0.00 (0.00%) As of 10/13/2026 Quince Therapeutics beat analyst earnings expectations in its Q2 2026 results, released August 14, 2026. The company reported EPS of -$12.31 versus the -$28.02 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 14, 2026TimeBefore Market OpensConference Call7:00 AM ET Quince Therapeutics EPS ResultsActual EPS-$12.31Consensus EPS -$28.02Beat/MissBeat by +$15.71One Year Ago EPSN/AEPS Beat Rate2 of last 6 quartersQuince Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Quince Therapeutics Q2 2026 Earnings FAQ Did Quince Therapeutics beat earnings estimates for Q2 2026? Quince Therapeutics (NASDAQ:QNCX) reported earnings of -$12.31 per share for Q2 2026, beating the consensus estimate of -$28.02. The report was announced on Friday, August 14, 2026. Quince Therapeutics Earnings HeadlinesQuince Therapeutics, Inc. (NASDAQ:QNCX) Stock Has Consensus Price Target of $189.88 According to AnalystsNovember 13 at 3:15 AM | americanbankingnews.comQuince Therapeutics (QNCX) Set to Release Quarterly Earnings on WednesdayNovember 10, 2026 | americanbankingnews.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount. | Base Camp Trading (Ad)Quince Therapeutics Renames as IRulya Therapeutics, Advances Pulmonary Drug DevelopmentOctober 9, 2026 | finance.yahoo.comQuince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary DiseaseOctober 9, 2026 | globenewswire.comQuince Shareholders Approve New Equity and Stock PlansOctober 6, 2026 | tipranks.comSee More Quince Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Quince Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quince Therapeutics and other key companies, straight to your email. Email Address About Quince TherapeuticsQuince Therapeutics (NASDAQ:QNCX) is a biotechnology company focused on developing treatments for rare diseases. Its principal program has been EryDex, an investigational therapy designed to deliver dexamethasone sodium phosphate inside a patient’s own red blood cells. The company developed EryDex for ataxia-telangiectasia, a rare inherited disorder that can cause progressive neurological and immune-system problems. The treatment uses a process intended to load the drug into red blood cells for gradual release. Quince’s program followed its 2023 combination with EryDel, the company that developed the EryDex technology. EryDex was evaluated in a Phase 3 clinical trial, which did not meet its primary efficacy endpoint. Quince is headquartered in the United States; its work on EryDex grew out of technology developed by EryDel in Europe.View Quince Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?Applied Materials Beats and Raises, But Investors Stay Unconvinced3 Power and Grid Stocks That Could Keep Growing Even if AI Spending SlowsYETI Beat on Earnings, But Its Sales Tell a Different Story Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.